Twenty-four months RFS and updated toxicity data from OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in stage III melanoma.

Elisa A. Rozeman,Irene L.M. Reijers,Esmée P. Hoefsmit,Karolina Sikorska,Oscar Krijgsman,Bart A. van de Wiel,Petros Dimitriadis,Hanna Eriksson,Maria Gonzalez,Lindsay G. Grijpink-Ongering,Ron M. Kerkhoven,Annegien Broeks,W.M.C. Klop,Andrew J. Spillane,Robyn P. M. Saw,Alexander C.J. van Akkooi,Richard A. Scolyer,Alexander M. Menzies,Georgina V. Long,Christian U. Blank

Twenty-four months RFS and updated toxicity data from OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in stage III melanoma.

2020

10015Background: Early results of the OpACIN-neo study testing 3 different dosing schedules of neoadjuvant IPI + NIVO demonstrated that 2 cycles IPI 1mg/kg + NIVO 3mg/kg (IPI1NIVO3, arm B) was the ...

Keywords:

Oncology
Stage III melanoma
Internal medicine
Ipilimumab
Nivolumab
toxicity data
Pathology
Dosing
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations